[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@john_hersc79276](/creator/twitter/john_hersc79276)
"$PRAX (1) Biotwit brainiacs - anyone else thinking this is a big deal or am I just reading wwwaaayyyy too much into this Ok so they did tipping point in the mITT population to assess robustness. Fine great. Results look decent"  
[X Link](https://x.com/john_hersc79276/status/1979188089290367054) [@john_hersc79276](/creator/x/john_hersc79276) 2025-10-17T14:09Z XXX followers, 18.2K engagements


"$PRAX (part 2) but the problem is they imputed that data only for the N=49 dropouts already in the mITT population and end of study NOT for the N=33 or so (e.g. XX% of patients) that were in safety population but not mITT population Regulator will not give a hoot about mITT"  
[X Link](https://x.com/john_hersc79276/status/1979188402114220401) [@john_hersc79276](/creator/x/john_hersc79276) 2025-10-17T14:11Z XXX followers, XXX engagements


"@houndcl @jfais20 and then the ADA/PK stuff is your domain but if the attenuation of response from week 6-12 is due to ADA development then the "benefit" is definitely not there in the long run Because whatever benefit exists will be transient for sure"  
[X Link](https://x.com/john_hersc79276/status/1979208011320013246) [@john_hersc79276](/creator/x/john_hersc79276) 2025-10-17T15:28Z XXX followers, XXX engagements